Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

RheumaGen raises $15M Series A for HLA gene editing in autoimmune diseases, while RyboDyn gets $4M pre-seed to study non-coding DNA for cancer immunotherapies ...

MLB free agency is cruising right along, with many of the big names, including Juan Soto, off the board. But some impact players are still available, and the trade market has been active. The ...